AI-materials startups will produce venture-scale outcomes on venture timescales (7–10 yrs).

Why the market believes it

Venture allocation presumes pharma-like exit profile.

Breaking conditions

Wildcat 18 yrs / $73M exit on $90-160M raised. Citrine 13 yrs / $76M / stalled. Kebotix 17→4 employees pre-acquisition. AIONICS -34.8% YoY.
2026-2027 capital-call cycle: Periodic, Lila, CuspAI hit Series-C without commercial AI-discovered material at volume.

Winners & losers if it breaks

Winners

Services with near-term revenue (Cubuk's pivot, Atinary, Matter Loop's 4 deals)
Growth equity / corporate-strategic models

Losers

$1B-priced discovery startups facing flat or down Series-C
Venture-scale-only allocators

Capital rotation

When it breaks — capital rotates from venture-scale discovery into growth equity / corporate-strategic / services-LaaS. Matter Loop's 4 deals and near-term revenue become an asset, not a limit.

All assumptions →